Answers are grounded in this paper and cite their sources.
The immunosuppressive tumor microenvironment (TME) is a major obstacle to effective cancer immunotherapy by promoting immune evasion and disease progression. Recent studies suggest that erythropoietin (EPO), a glycoprotein hormone traditionally associated with erythropoiesis, also functions as an emerging regulator of tumor immune remodeling in a context-dependent manner. Tumor-derived EPO can influence tumor-associated macrophages and type 1 conventional dendritic cells by engaging with the erythropoietin receptor (EPOR) expressed on those immune cell surfaces, thereby reshaping the immunosuppressive TME and facilitating immune escape. Targeting the EPO/EPOR axis has therefore emerged as a promising strategy for cancer immunotherapy, with anti-EPOR neutralizing antibodies, siRNA silencing and antagonists yielding encouraging preclinical efficacy. Nevertheless, clinical translation remains challenging because of the essential physiological role of EPO/EPOR signaling in erythropoiesis, potential off-target toxicity, and the difficulty of selectively blocking pathological signaling while preserving normal hematopoietic function. Nano delivery systems provide new opportunities for precise modulation of the EPO/EPOR axis by improving targeting specificity and minimizing systemic toxicity. This review systematically examines the evolving understanding of the EPO/EPOR axis in tumor immunity, discusses the advances and limitations of current targeting strategies, and highlights the opportunities of nano delivery systems for precision targeting of the EPO/EPOR axis in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: